November 23, 2018 | Featured
London, 23rd November 2018
Intract Pharma Limited is pleased to announce receipt of an award from the Bill & Melinda Gates Foundation to fund investigation of Intract’s Soteria® technology as a means to stabilise orally-administered therapeutic antibodies.
GI diseases caused by pathogens such as Enterotoxigenic Escherichia coli (ETEC) and Campylobacter are a major cause of morbidity and mortality in infants in the developing world, with ETEC alone responsible for an estimated 400 million cases of diarrhoea and 157,000 deaths/year.
Intract’s Soteria technology is a unique formulation which stabilises bio-therapeutic drugs within the GI tract, allowing the possibility for creation of oral formulations of complex biologic molecules which normally can only be administered by injection. Soteria will be utilised in the Gates Foundation-funded project to enhance the therapeutic effect of antibodies which specifically target the disease-causing bacteria without damaging the natural healthy microbiome.
Bill Lindsay, CEO of Intract said “Intract is extremely pleased to be working with the Bill & Melinda Gates Foundation on this exciting and important project. We believe that our technology and expertise in understanding the behaviour of drugs in the GI tract will maximise the chances of development of a unique, life-saving therapy”
About Intract Pharma
Intract Pharma is an oral drug delivery specialist, developing state-of-the-art formulation technologies and unique gastrointestinal models to develop advanced new therapeutics. Since its inception, Intract has pursued innovation in oral drug delivery as a means to improve on current therapies, making them safer and more effective for patients. Soteria® is available for license exclusively from Intract Pharma. For more information visit www.intractpharma.com
Copyright © 2018 Intract Pharma
Website Design by Creative Brand Design